Crism losses widen as it spends on clinical development
26th Jun 2026 12:43
(Sharecast News) - Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.
Read moreCrism losses widen as it spends on clinical development
26th Jun 2026 12:43
(Sharecast News) - Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.
Read moreCrism reports positive preclinical results from prostate cancer model
21st Apr 2026 15:14
(Sharecast News) - Crism Therapeutics reported positive preclinical results for its Docetaxel-ChemoSeed implant on Tuesday, highlighting improved efficacy and tolerability compared with standard chemotherapy in a prostate cancer model.
Read moreCrism Therapeutics gets clearance for UK phase 2 trial
1st Sep 2025 14:54
(Sharecast News) - Crism Therapeutics said on Monday that it has received both regulatory clearance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and ethical approval from a UK Research Ethics Committee to begin its registration-grade phase two trial of irinotecan-ChemoSeed in glioblastoma patients.
Read moreCrism reports progress with ChemoSeed drug delivery platform
26th Aug 2025 11:02
(Sharecast News) - Crism Therapeutics used its annual general meeting on Tuesday to highlight progress on its ChemoSeed drug delivery platform as it advances towards key clinical milestones.
Read more